BRICANYL TURBOHALER 500 Mcg/Dose Powder for Inhalation
Země: Irsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
Charakteristika produktu
(SPC)
26-04-2024
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
TERBUTALINE SULFATE
Dostupné s:
IMED Healthcare Ltd.
INN (Mezinárodní Name):
TERBUTALINE SULFATE
Dávkování:
500 Mcg/Dose
Léková forma:
Powder for Inhalation
Druh předpisu:
Product subject to prescription which may be renewed (B)
Stav Autorizace:
Withdrawn
Datum autorizace:
2014-05-28
Charakteristika produktu
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Bricanyl Turbohaler 500 micrograms per metered dose, inhalation powder.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each metered dose contains 500 micrograms of Terbutaline Sulphate.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Inhalation powder
_Product imported from the UK:_
Multi-dose breath-actuated metered dose powder inhaler. White to off white spherical particles which break into a fine
powder on inhalation.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Terbutaline is a selective beta
2
-adrenergic agonist recommended for the relief and prevention of bronchospasm in
bronchial asthma and in chronic bronchitis and other bronchopulmonary disorders in which bronchospasm is a
complicating factor.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults and Children: One inhalation (500 micrograms) (metered dose) as required. Not more than 4 inhalations should
be necessary in any 24 hour period.
Elderly: Dosage as for adults.
Instructions for use and cleaning are provided in the Patient Information Leaflet, which can be found in each pack.
4.3 CONTRAINDICATIONS
Bricanyl preparations are contra-indicated in patients with a history of sensitivity to terbutaline sulphate.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed in proper use and their inhalation technique checked regularly.
With each inhalation a fraction of the delivered dose will be deposited in the oral cavity. To minimize unnecessary
systemic exposure to terbutaline, the patients should be advised to, when possible, rinse their mouth after each use.
If a previously effective dosage regimen no longer gives the same symptomatic relief, the patient should urgently seek
further medical advice. Consideration should be
Přečtěte si celý dokument
